StemRIM Inc. (4599.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 173.00

From 52W high−52.10%

Volume520300.00

Market capJPY 10.63B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

JPY 173.00

From 52W high

−52.10%

Volume

520300.00

Market cap

JPY 10.63B

ValuationView details →

P/E (Fwd)

108.1x

EV/EBITDA

−2.7x

P/E (TTM)

—

RSI (14)

21.1

MomentumView details →

1D Return

−3.39%

YTD Return

−32.70%

ValuationView details →

P/E (Fwd)

108.1x

P/E (TTM)

—

EV/EBITDA

−2.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−27.52%

ROA (TTM)

−26.56%

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

+13.24%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+5.52%

EBITDA YoY

—

MomentumView details →

1D Return

−3.39%

YTD Return

−32.70%

1Y Return

−40.60%

RSI (14)

21.1

vs 50D SMA

−41.29%

vs 200D SMA

−39.77%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

53.71x

Quick Ratio

53.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

−1.90B

Op. CF (TTM)

—

Next earningsDec 16, 2026 →

Latest newsMore news →

Japanese stocks fell on September 11, 2026, with StemRIM leading decliners on the Tokyo Stock Exchange Growth Market after announcing clinical trial results for Redasemtide.10d ago

StemRim announced results of clinical trials for 'Redasemtide' in epidermolysis bullosa and acute ischemic stroke patients, with the stroke trial failing to meet its primary endpoint.12d ago

Similar companies

Immuno-Biological Laboratories Co.,Ltd.4570.T WAKAMOTO PHARMACEUTICAL CO.,LTD.4512.T KAINOS Laboratories,Inc.4556.T K Pharma,Inc.4896.T MORISHITA JINTAN CO.,LTD.4524.T AnGes,Inc.4563.T Find similar companies →

Latest newsMore news →

Japanese stocks fell on September 11, 2026, with StemRIM leading decliners on the Tokyo Stock Exchange Growth Market after announcing clinical trial results for Redasemtide.10d ago StemRim announced results of clinical trials for 'Redasemtide' in epidermolysis bullosa and acute ischemic stroke patients, with the stroke trial failing to meet its primary endpoint.12d ago StemRim reported its fiscal year results for the year ended July 2026, with a net loss of 1.85 billion yen, narrowing from a 1.92 billion yen loss in the prior year, marking the third consecutive year of losses.12d ago